Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Phase 3 Completed 1098 enrolled H. Lundbeck A/S

RandomizedParallel-groupDouble-blindTreatment

To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)

Evaluation	Drug	Modality	Dose	Route
Subject	Lu AF35700	Unknown	10 mg	Oral
Subject	Lu AF35700	Unknown	20 mg	Oral
Subject	Olanzapine	Small molecule	15 mg	Oral
Subject	Olanzapine	Small molecule	20 mg	Oral
Subject	Risperidone	Other / unclassified	4 mg	Oral
Subject	Risperidone	Other / unclassified	6 mg	Oral